Related Experiment Video
Updated: Jul 11, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
[The dynamin-2-gene related centronuclear myopathy]
1Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France.
Autosomal dominant centronuclear myopathy (AD-CNM) is a rare genetic muscle disorder caused by DNM2 gene mutations. Research is exploring new therapies targeting DNM2 expression for clinical trials.
Area of Science:
- Genetics and Molecular Biology
- Neuromuscular Disorders
Context:
- Autosomal dominant centronuclear myopathy (AD-CNM) is a rare congenital myopathy.
- It is characterized by muscle weakness and centrally located nuclei in muscle fibers.
- AD-CNM is caused by mutations in the DNM2 gene, encoding dynamin 2 (DNM2).
Purpose:
- To review the pathophysiology of AD-CNM.
- To highlight the clinical and histopathological features of AD-CNM.
- To discuss emerging therapeutic strategies for AD-CNM.
Summary:
- DNM2 mutations lead to a spectrum of AD-CNM, affecting muscle homeostasis through various mechanisms.
- Pathophysiological defects include issues with excitation-contraction coupling, muscle regeneration, mitochondria, and autophagy.
- Histopathological hallmarks include nuclear centralization and type 1 myofiber abnormalities.
Impact:
- Understanding AD-CNM mechanisms informs the development of targeted therapies.
- Therapeutic approaches include modulating DNM2 expression or allele-specific silencing.
- These strategies pave the way for clinical trials in AD-CNM patients.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Animal Mitochondrial Genetics
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy

